Terrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.
Terrill Jordan
Advertisement
Articles by Terrill Jordan
Advertisement
Latest Updated Articles
Plans to Implement Fee-for-Value Models in OncologyPublished: November 17th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
5